KR102533599B1 - 단백질 티로신 포스파타제 억제제 및 이의 사용 방법 - Google Patents

단백질 티로신 포스파타제 억제제 및 이의 사용 방법 Download PDF

Info

Publication number
KR102533599B1
KR102533599B1 KR1020217032888A KR20217032888A KR102533599B1 KR 102533599 B1 KR102533599 B1 KR 102533599B1 KR 1020217032888 A KR1020217032888 A KR 1020217032888A KR 20217032888 A KR20217032888 A KR 20217032888A KR 102533599 B1 KR102533599 B1 KR 102533599B1
Authority
KR
South Korea
Prior art keywords
alkyl
hydroxy
fluoro
trione
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217032888A
Other languages
English (en)
Korean (ko)
Other versions
KR20210151821A (ko
Inventor
앤드류 보그단
제프 티. 할보르센
엘리오트 피. 파네이
제니퍼 엠. 프로스트
필립 알. 킴
마크 에이. 매툴렌코
매튜 오'코너
레자 시루디
에릭 보이트
자오밍 시옹
칭웨이 아이. 장
크리스티나 바움가르트너
제이슨 애보트
크리스토스 이코노모우
스테이시 포수
Original Assignee
칼리코 라이프 사이언시스 엘엘씨
애브비 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칼리코 라이프 사이언시스 엘엘씨, 애브비 인코포레이티드 filed Critical 칼리코 라이프 사이언시스 엘엘씨
Priority to KR1020237016132A priority Critical patent/KR20230074822A/ko
Publication of KR20210151821A publication Critical patent/KR20210151821A/ko
Application granted granted Critical
Publication of KR102533599B1 publication Critical patent/KR102533599B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217032888A 2019-03-14 2020-03-13 단백질 티로신 포스파타제 억제제 및 이의 사용 방법 Active KR102533599B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237016132A KR20230074822A (ko) 2019-03-14 2020-03-13 단백질 티로신 포스파타제 억제제 및 이의 사용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818447P 2019-03-14 2019-03-14
US62/818,447 2019-03-14
PCT/US2020/022717 WO2020186199A1 (en) 2019-03-14 2020-03-13 Protein tyrosine phosphatase inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237016132A Division KR20230074822A (ko) 2019-03-14 2020-03-13 단백질 티로신 포스파타제 억제제 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20210151821A KR20210151821A (ko) 2021-12-14
KR102533599B1 true KR102533599B1 (ko) 2023-05-17

Family

ID=70190226

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217032888A Active KR102533599B1 (ko) 2019-03-14 2020-03-13 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
KR1020237016132A Ceased KR20230074822A (ko) 2019-03-14 2020-03-13 단백질 티로신 포스파타제 억제제 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237016132A Ceased KR20230074822A (ko) 2019-03-14 2020-03-13 단백질 티로신 포스파타제 억제제 및 이의 사용 방법

Country Status (24)

Country Link
US (1) US10851073B2 (enExample)
EP (1) EP3938038A1 (enExample)
JP (3) JP7204005B2 (enExample)
KR (2) KR102533599B1 (enExample)
CN (2) CN116332873A (enExample)
AR (1) AR118374A1 (enExample)
AU (1) AU2020234712B2 (enExample)
BR (1) BR112021017430A2 (enExample)
CA (1) CA3131894A1 (enExample)
CL (2) CL2021002382A1 (enExample)
CO (1) CO2021013524A2 (enExample)
CR (1) CR20210516A (enExample)
DO (1) DOP2021000188A (enExample)
EC (1) ECSP21075909A (enExample)
IL (2) IL286373B1 (enExample)
MA (1) MA55301A (enExample)
MX (2) MX2021010544A (enExample)
MY (1) MY209419A (enExample)
PE (1) PE20212154A1 (enExample)
PH (1) PH12021552194A1 (enExample)
SG (1) SG11202109067PA (enExample)
TW (2) TWI849082B (enExample)
UY (1) UY38613A (enExample)
WO (1) WO2020186199A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552194A1 (en) * 2019-03-14 2022-08-22 Abbvie Inc Protein tyrosine phosphatase inhibitors and methods of use thereof
EP4077291A1 (en) * 2019-12-18 2022-10-26 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof
JP2023542503A (ja) * 2020-09-11 2023-10-10 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
AU2022219025A1 (en) * 2021-02-12 2023-08-24 Recovery Therapeutics, Inc. Compounds, compositions, and methods for modulating fgf activity
EP4305030A4 (en) * 2021-03-11 2025-05-21 Kumquat Biosciences Inc. HETEROCYCLES AND THEIR USES
WO2022261145A1 (en) * 2021-06-10 2022-12-15 Ness Therapeutics, Inc. Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
CN118556055A (zh) * 2021-11-11 2024-08-27 卡里科生命科学有限责任公司 蛋白酪氨酸磷酸酶抑制剂及其使用方法
WO2023086498A1 (en) * 2021-11-11 2023-05-19 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
IL314650A (en) * 2022-02-02 2024-09-01 Nerio Therapeutics Inc Protein tyrosine phosphatase inhibitors and uses thereof
US20250136564A1 (en) * 2022-02-02 2025-05-01 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
WO2023150150A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
US20250206757A1 (en) * 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
CN119790052A (zh) * 2022-09-13 2025-04-08 金橘生物科技公司 苯并稠合的n-杂环及其用途
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
WO2024141015A1 (en) * 2022-12-30 2024-07-04 Insilico Medicine Ip Limited Protein tyrosine phosphatase inhibitors and uses thereof
WO2025011570A1 (zh) * 2023-07-11 2025-01-16 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
AR133250A1 (es) 2023-07-14 2025-09-10 Univ Leuven Kath Nuevos compuestos
WO2025026158A1 (zh) * 2023-07-28 2025-02-06 杭州中美华东制药有限公司 具有ptpn2抑制作用的化合物及其用途
TW202519218A (zh) * 2023-08-02 2025-05-16 美商耐瑞歐醫療公司 蛋白質酪胺酸磷酸酶抑制劑之組合
WO2025055985A1 (zh) * 2023-09-15 2025-03-20 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
CN120004876A (zh) * 2023-11-16 2025-05-16 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
WO2025136841A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Substituted isoquinoline derivatives and methods of use thereof
WO2025242216A1 (zh) * 2024-05-24 2025-11-27 杭州百新生物医药科技有限公司 吲哚啉类化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067612A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
WO2019246513A1 (en) 2018-06-21 2019-12-26 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
AU2002342859B2 (en) 2001-10-30 2007-07-26 Merck Serono Sa Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPS)
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
CA2647472A1 (en) * 2006-03-31 2007-10-11 Novartis Ag Organic compounds
US20100160228A1 (en) 2007-05-23 2010-06-24 Valtion Teknillinen Tutkimuskeskus Method for inhibiting or stimulating angiogenesis in an individual
AR066820A1 (es) * 2007-06-04 2009-09-16 Novartis Ag Compuestos de tiadiazolidin-3 ona
WO2010008852A2 (en) 2008-06-23 2010-01-21 Taiga Biotechnologies, Inc. Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder
WO2010118241A2 (en) 2009-04-08 2010-10-14 Indiana University Research & Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2011057331A1 (en) 2009-11-11 2011-05-19 Monash University A method for treating obesity
US20130202577A1 (en) 2010-02-03 2013-08-08 Monash University Diagnostic and prognostic assay for breast cancer
HK1211293A1 (en) * 2012-11-02 2016-05-20 辉瑞公司 Bruton's tyrosine kinase inhibitors
CA2977839C (en) 2014-02-28 2022-07-26 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
US20170224731A1 (en) 2014-06-10 2017-08-10 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
JP6507234B2 (ja) * 2014-10-02 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物
WO2017078499A2 (ko) 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
US20180325925A1 (en) 2015-11-06 2018-11-15 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase inhibitor
WO2018148378A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
US11273166B2 (en) 2017-06-13 2022-03-15 Monash University Methods and compositions for the treatment of obesity
US11597739B2 (en) 2017-08-24 2023-03-07 The Royal Institution For The Advancement Of Learning/Mcgill University Enhancing CD8+ T cells for adoptive T cell therapy by inhibiting PTPN1 (PTP1B) and PTPN2 (TC-PTP)
PH12021552194A1 (en) * 2019-03-14 2022-08-22 Abbvie Inc Protein tyrosine phosphatase inhibitors and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067612A1 (en) * 2005-12-08 2007-06-14 Novartis Ag 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
WO2019246513A1 (en) 2018-06-21 2019-12-26 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
CN114025844A (zh) 2022-02-08
WO2020186199A1 (en) 2020-09-17
KR20210151821A (ko) 2021-12-14
IL286373A (en) 2021-10-31
CN116332873A (zh) 2023-06-27
CN114025844B (zh) 2022-07-26
BR112021017430A2 (pt) 2022-01-18
MX2024010859A (es) 2024-09-11
JP2022522526A (ja) 2022-04-19
UY38613A (es) 2020-09-30
CL2024001723A1 (es) 2024-11-22
PE20212154A1 (es) 2021-11-09
KR20230074822A (ko) 2023-05-31
SG11202109067PA (en) 2021-09-29
IL324019A (en) 2025-12-01
JP7617890B2 (ja) 2025-01-20
PH12021552194A1 (en) 2022-08-22
EP3938038A1 (en) 2022-01-19
TWI849082B (zh) 2024-07-21
JP7204005B2 (ja) 2023-01-13
CO2021013524A2 (es) 2022-02-28
AU2020234712A1 (en) 2021-09-09
JP2025061064A (ja) 2025-04-10
MA55301A (fr) 2022-01-19
CR20210516A (es) 2022-07-19
CA3131894A1 (en) 2020-09-17
US10851073B2 (en) 2020-12-01
CL2021002382A1 (es) 2022-06-03
JP2023052094A (ja) 2023-04-11
TW202100515A (zh) 2021-01-01
AU2020234712B2 (en) 2025-12-04
AR118374A1 (es) 2021-09-29
IL286373B1 (en) 2025-11-01
MY209419A (en) 2025-07-08
US20200299246A1 (en) 2020-09-24
DOP2021000188A (es) 2022-03-15
TW202519515A (zh) 2025-05-16
MX2021010544A (es) 2021-10-01
ECSP21075909A (es) 2021-11-30

Similar Documents

Publication Publication Date Title
KR102533599B1 (ko) 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
JP7704787B2 (ja) タンパク質チロシンホスファターゼ阻害剤及びそれらの使用方法
JP2022533023A (ja) 統合的ストレス経路の調節剤としての置換シクロアルキル
CN116829555A (zh) 蛋白酪氨酸磷酸酶抑制剂及其使用方法
CN116348455A (zh) 蛋白质酪氨酸磷酸酶抑制剂和其使用方法
CN115443276A (zh) 吡啶并嘧啶酮衍生物及其作为芳烃受体调节剂的应用
WO2020038387A1 (zh) 高活性sting蛋白激动剂
CN115066423B (zh) Pd-l1拮抗剂化合物
RU2833220C2 (ru) Ингибиторы белковых тирозинфосфатаз и способы их применения
RU2799446C2 (ru) Ингибиторы протеин-тирозинфосфатазы и способы их применения
WO2025209533A1 (zh) 一种pan-RAS抑制剂化合物
CN117580824A (zh) 整合应激通路的调节剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20211013

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220329

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20220329

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220712

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230213

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230512

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230512

End annual number: 3

Start annual number: 1

PG1601 Publication of registration